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Objectives The aim of this study was to describe differences in treatment and in-hospital mortality
of early, late, and very late stent thrombosis (ST).
Background Early, late, and very late ST may differ in clinical presentation, management, and in-
hospital outcomes.
Methods We analyzed deﬁnite (angiographically documented) ST cases identiﬁed from February
2009 to June 2010 in the CathPCI Registry. We stratiﬁed events by timing of presentation: early (1
month), late (1 to 12 months), or very late (12 months) following stent implantation. Multivariable
logistic regression modeling was performed to compare in-hospital mortality for each type of ST
after adjusting for baseline comorbidities.
Results During the study period, 7,315 ST events were identiﬁed in 7,079 of 401,662 patients (1.8%)
presenting with acute coronary syndromes. This ST cohort consisted of 1,391 patients with early ST
(19.6%), 1,370 with late ST (19.4%), and 4,318 with very late ST (61.0%). Subjects with early ST had a
higher prevalence of black race and diabetes, whereas subjects with very late ST had a higher preva-
lence of white race and a lower prevalence of prior myocardial infarction or diabetes. In-hospital mortal-
ity was signiﬁcantly higher in early ST (7.9%) compared with late (3.8%) and very late ST (3.6%, p  0.001).
This lower mortality for late and very late ST persisted after multivariable adjustment (odds ratio:
0.53 [95% conﬁdence interval (CI): 0.36 to 0.79] and 0.58 [95% CI: 0.43 to 0.79], respectively).
Conclusions Signiﬁcant differences exist in the presentation and outcomes of early, late, and very late ST.
Among patients with acute coronary syndromes who are undergoing percutaneous coronary intervention for
angiographically documented ST, early ST is associated with the highest in-hospital mortality. (J Am Coll
Cardiol Intv 2012;5:131–40) © 2012 by the American College of Cardiology Foundation
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132Stent thrombosis (ST) is an uncommon but highly morbid
complication of percutaneous coronary intervention (PCI),
with 10% to 20% mortality at 1 year (1–4). Causes of ST can
be grouped according to factors related to the stent, the
procedure, and the patient (5). Early ST (occurring within 1
month of stent implantation) is more commonly due to
procedure-related complications (6). In contrast, late ST (oc-
curring 1 to 12 months after stent implantation) and very late
See page 141
ST (occurring12 months after stent implantation) may be
caused by impaired re-endothelialization, stent malapposi-
tion or fracture, a hypersensitivity reaction to the polymer used
in drug-eluting stents (DES), or de novo plaque rupture
(7–10). Inadequate antiplatelet therapy and/or resistance to
antiplatelet agents are also associated with an increased risk for
ST (11,12). DES have a similar rate of early and late ST
relative to bare-metal stents (BMS), but DES may be associ-
ated with increased rates of very
late ST (13). These heterogeneous
causes of ST may result in differ-
ent presentations and outcomes
for early, late, and very late ST.
Prior studies have identified
clinical predictors of ST after stent
implantation (2,14,15), but most
of these studies have limited
power to detect differences in rates
of major adverse cardiovascular
events with treatment for early,
late, or very late ST. To address
this gap in knowledge, we identi-
fied definite, angiographically
documented, ST in the CathPCI
registry and analyzed differences in the presentation, treatment,
and in-hospital mortality of ST as a function of time since
original stent implantation.
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Study population. The CathPCI registry (version 4.3) is an
nitiative of the American College of Cardiology Founda-
ion and the Society for Cardiovascular Angiography and
nterventions. The registry receives data from over 1,000
articipating hospitals across the United States, and its
atabase includes demographic factors, procedural details,
nd in-hospital outcomes of patients undergoing coronary
ngiography and PCI. The CathPCI registry is composed
f standard data collection forms with explicit data defini-
ions, uniform data entry and transmission requirements,
nd data quality checks (16). The NCDR (National Car-
iovascular Data Registry) has a data quality program in
lace to ensure consistent and reliable data. The institu-
ional review board of each hospital approved participation
n the CathPCI registry. Participating sites collected data in
n anonymous fashion for consecutive patients who met the
nclusion criteria during the initial hospitalization. Built-in
ata quality checks include exclusion of outliers, edit checks
t time of entry, consistency checks, quarterly reports, and
andom site audits by trained abstractors. In addition,
articipating facilities are afforded a wide variety of training
ptions. Details on the data collection process have previ-
usly been published, and the data definitions can be found
t NCDR’s Website (17). All data elements were proposed
y the CathPCI Version 4 Dataset Workgroup, reviewed by
he CathPCI Steering Committee, and approved by the
CDR Science Quality and Oversight Committee. Data
lements are recorded at the time of cardiac catheterization
nd then forwarded electronically to a secure data server
tored at the ACC Heart House in Washington, DC.
For this study, we examined registry patients undergoing
CI procedures from February 3, 2009, through June 29,
010. ST was identified using a pre-defined data element
or ST by the participating centers at the time of PCI
ccording to Figure 1. To ensure quality of data recording
nd to model closely the Academic Research Consortium
efinition of definite ST (18), we also required the angiog-
apher to indicate that the patient presented with an acute
oronary syndrome; that a prior PCI had occurred; and that
T was present. To refine the cohort, we excluded any
ubject in which the lesion was encoded as a chronic total
cclusion or if the date of implantation of the thrombosed
tent was missing or unknown. Furthermore, in cases where
nitial flow was categorized as Thrombolysis In Myocardial
nfarction (TIMI) flow grade 3, the case was excluded if the
perator failed to indicate the presence of visible thrombus
t the time of intervention. Early ST was defined as
ccurring within 1 month of prior stent implantation, late as
to 12 months, and very late as 1 year.
Baseline demographics and procedural details were reported
y participating centers. Race/ethnicity was based on patient or
amily self-report, with options consisting of white, black,
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133Hispanic, Asian, Native American, or other. Because the
CathPCI registry only contains data related to a given PCI
procedure (i.e., there is no ability to link patients across
different interventions), procedural details of the initial stent
implantation could not be ascertained other than the initial
stent type (BMS vs. DES). This study was approved by the
Duke University Medical Center and was determined to meet
criteria for research not requiring informed consent.
Clinical endpoints. The primary endpoint was in-hospital
mortality. Secondary endpoints during the hospital admis-
sion included occurrence of a cerebrovascular event (defined
as a focal neurologic deficit lasting24 h due to an ischemic
r hemorrhagic cause), a bleeding event within 72 h
defined as 3 g/dl drop in hemoglobin, transfusion of
hole blood or packed red blood cells, or an intervention or
urgical procedure to correct bleeding related to the PCI),
nd lesion treatment success (defined as TIMI flow grade 3
n the culprit vessel at the conclusion of the procedure).
Statistical analysis. Baseline patient subgroups are presented
s counts with percentages for categorical variables and
edian with interquartile range for continuous variables.
tatistical comparison of between-group differences was
erformed using chi-square test for categorical variables and
nalysis of variance or the Kruskal-Wallis test for continuous
ariables. Statistical significance was defined as p 0.05 for all
omparisons. All statistical analyses were performed by the
uke Clinical Research Institute using SAS (version 9.3, SAS
nstitute, Cary, North Carolina).
Multivariable logistic regression modeling with general-
Figure 1. Study Population
Records retrieved from the CathPCI registry database (version 4.3). ACS  acu
ST  stent thrombosis; TIMI  Thrombolysis In Myocardial Infarction.zed estimating equations was performed to evaluate if theiming of ST was an independent predictor of in-hospital
ortality while adjusting for within hospital correlation
sing a previously validated model for mortality after PCI
19). Early ST was used as the reference group. Variables in
he mortality model included: age, sex, race, presentation
ith ST-segment elevation myocardial infarction (STEMI),
ardiogenic shock, previous heart failure, cerebrovascular
isease, peripheral vascular disease, chronic lung disease,
lomerular filtration rate, dialysis, New York Heart Asso-
iation functional class heart failure, highest risk segment
ategory, PCI status, diabetes, and lesion bifurcation.
esults
A total of 7,315 ST cases with known timing occurred in
7,079 patients at 977 hospitals during the study period
(Fig. 1). Stent thromboses represented 1.8% of all PCI for
acute coronary syndromes during the study period. A total
of 1,391 early, 1,370 late, and 4,318 very late ST were
identified, representing 19.6%, 19.4%, and 60% of the study
population, respectively. Among subjects with very late ST,
925 (21.4%) occurred 1 to 2 years after an index PCI, and
3,393 (78.6%) occurred 2 years after index PCI.
Patient characteristics differed based on the timing of ST
(Table 1). The prevalence of black race, diabetes, and prior
heart failure was highest among subjects with early ST, and
these subjects were more likely to present with cardiogenic
shock than the other ST groups were. Patients with late ST
were more likely to have previous coronary artery bypass
nary syndrome(s); PCI  percutaneous coronary intervention;te corograft and renal failure and to present with unstable angina
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134rather than acute myocardial infarction. The group present-
ing with very late ST had the highest prevalence of white
race and a lower prevalence of prior myocardial infarction,
renal failure, or diabetes.
Most patients had TIMI flow grade 0 (complete throm-
botic occlusion) on initial coronary angiography (Table 2);
TIMI flow grade 0 was more common in early ST (82%) than
in late (61.9%) or very late ST (68.3%). The culprit lesion was
more commonly located in the left anterior descending coro-
nary artery (48%) in patients with early and late ST, whereas
Table 1. Demographic Factors and Presentation of P
Early ST
(n  1,391)
Age, yrs 61.0 (52–71)
Male 933 (67.1)
Race/ethnicity
White 1,150 (82.7)
Black 189 (13.6)
Asian 30 (2.2)
Hispanic 90 (5.6)
Body mass index, kg/m2 29.0 (25–34)
Current/recent smoker 582 (41.8)
HTN 1,193 (85.8)
Dyslipidemia 1,191 (85.6)
Family history of CAD 317 (22.8)
Prior MI 988 (71.0)
Prior HF 237 (17.0)
Prior CABG 204 (14.7)
GFR 73.9 (57–91)
Dialysis 50 (3.6)
Cerebrovascular disease 184 (13.2)
Peripheral vascular disease 204 (14.7)
Chronic lung disease 264 (19.0)
Diabetes 608 (43.7)
Noninsulin-requiring 346 (24.9)
Insulin-requiring 262 (18.8)
Type of previous stent
BMS 456 (32.8)
DES 827 (59.5)
Unknown 104 (7.5)
Symptoms on admission
Unstable angina 156 (11.2)
NSTEMI 306 (22.0)
STEMI 929 (66.8)
Pre-procedure shock 155 (11.1)
Pre-procedure IABP 8 (4.4)
Cardiac arrest 87 (6.3)
Cardiogenic shock 186 (13.4)
Values are median (interquartile range) or n (%).
BMS bare-metal stent(s); CABG coronary artery bypass graft; CA
filtration rate (calculated using the MDRD [Modification of Diet in Ren
intra-aortic balloon pump;MImyocardial infarction; NSTEMI non–
ST-segment elevation myocardial infarction.ST of the right coronary artery was more common (38%)among subjects with very late ST. Aspiration thrombectomy
was performed in 29% to 34% of patients. More than one-half
of patients had a new stent placed during treatment for ST.
The rate of new stent placement was lowest in early ST
(51.2%) and highest in very late ST (69.9%). A new DES was
placed in 47% of patients with very late ST, and 23% of
patients had a BMS placed (Fig. 2). Subjects with ST of a
previously implanted DES were more likely to have a new
DES placed as treatment for the ST event. Subjects with ST of
a previously implanted BMS were more likely to have a BMS
s With ST
Late ST
n  1,370)
Very Late ST
(n  4,318) p Value
60.0 (50–70) 61.0 (53–69) 0.02
980 (71.5) 3,325 (77.0) 0.001
0.001
,159 (84.6) 3,900 (90.3) 0.001
158 (11.5) 294 (6.8) 0.001
28 (2.0) 62 (1.4) 0.10
96 (7.0) 169 (3.9) 0.001
28.4 (25–33) 28.6 (25–33) 0.17
611 (44.6) 1,798 (41.6) 0.15
,199 (87.5) 3,648 (84.5) 0.02
,208 (88.2) 3,861 (89.4) 0.001
359 (26.2) 1,028 (23.8) 0.09
989 (72.2) 2,920 (67.6) 0.002
226 (16.5) 461 (10.7) 0.001
329 (24.0) 576 (13.3) 0.001
70.1 (54–90) 72.6 (58–90) 0.012
57 (4.2) 58 (1.3) 0.001
195 (14.2) 462 (10.7) 0.001
226 (16.5) 505 (11.7) 0.001
252 (18.4) 659 (15.3) 0.001
513 (37.5) 1,207 (28.0) 0.001
272 (19.9) 821 (19.0)
241 (17.6) 386 (8.9)
0.001
421 (30.7) 738 (17.1)
785 (57.3) 2,374 (54.5)
161 (11.8) 1,194 (27.7)
0.001
295 (21.5) 462 (10.7)
362 (26.4) 954 (22.1)
713 (52.0) 2,902 (67.2)
111 (8.1) 356 (8.2) 0.003
5 (4.2) 13 (3.3) 0.97
69 (5.0) 267 (6.2) 0.26
142 (10.4) 402 (9.3) 0.001
ronary artery disease; DES drug-eluting stent(s); GFR glomerular
se] study equation); HF heart failure; HTN hypertension; IABP
ent elevationmyocardial infarction; ST stent thrombosis; STEMIatient
(
1
1
1
D co
al Disea
ST-segmplaced as treatment for the ST event if the event was early or
s
m
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a
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135late. Among subjects with very late ST, the rate of new DES
placement was similar irrespective of the type of stent associ-
ated with the ST (47% vs. 48% for previously implanted DES
and BMS, respectively).
Approximately 10% of patients required mechanical support
during the procedure. Heparin was the most frequent anti-
thrombotic agent, followed by bivalirudin. Glycoprotein IIb/
IIIa inhibitors and prasugrel were used with increased fre-
quency in early ST compared with late or very late ST. Success
of lesion treatment was slightly lower in early ST (91.6%) than
Table 2. Intraprocedural Characteristics of Patients
Angiographic characteristics
Pre-Procedure TIMI ﬂow grade
0
1–2
3
Culprit lesion location
LAD
RCA
Circumﬂex
Bypass graft
Left main
Lesion length, mm
Bifurcation lesion
Procedural characteristics
Thrombectomy performed
Additional stent placed
DES
BMS
No stent placed
IABP or other mechanical support placed during procedu
Dissection
Coronary perforation
Post-procedure TIMI ﬂow grade
3
0–2
Intraprocedural medications
Anticoagulants
Unfractionated heparin
Bivalirudin
LMWH
Fondaparinux
Aspirin
Glycoprotein IIb/IIIa inhibitor
Thienopyridines
Clopidogrel
Prasugrel
Ticlopidine
Values are n (%).
LAD left anterior descending artery; LMWH low molecular-wei
Infarction; other abbreviations as in Table 1.late (93.9%) or very late ST (94.6%, p  0.026). lPatients with early ST had a greater likelihood of stroke
(1%) and major bleeding events (5.4%) than patients with late
or very late ST did (p  0.001 for stroke; p  0.003 for
bleeding) (Table 3). Unadjusted in-hospital mortality was
higher for early ST (7.9%) than for late (3.8%) or very late ST
(3.6%, p 0.001). Mortality was higher for early ST across the
pectrum of acute coronary syndromes, with the highest
ortality in patients with STEMI due to early ST (Fig. 3).
hese mortality trends were similar for patients with ST from
DES or BMS (Fig. 4). The lower mortality for late and very
T
Early ST
(n  1,391)
Late ST
(n  1,370)
Very Late ST
(n  4,318) p Value
0.001
1,141 (82.0) 848 (61.9) 2,948 (68.3)
150 (10.8) 330 (24.1) 872 (20.2)
96 (6.9) 191 (13.9) 489 (11.3)
0.001
666 (48.0) 541 (39.6) 1,728 (40.2)
371 (26.8) 433 (31.7) 1,635 (38.0)
282 (20.3) 217 (15.9) 610 (14.2)
51 (3.7) 160 (11.7) 310 (7.2)
17 (1.2) 17 (1.2) 21 (0.5)
18.4 (11.2) 20.3 (12.8) 21.3 (11.9) 0.001
240 (17.3) 204 (14.9) 603 (14.0) 0.010
447 (32.1) 401 (29.3) 1,475 (34.2) 0.003
0.001
374 (26.9) 482 (35.2) 2,031 (47.0)
338 (24.3) 284 (20.7) 988 (22.9)
679 (48.8) 604 (44.1) 1,299 (30.1)
186 (13.4) 119 (8.7) 403 (9.3) 0.001
28 (2.0) 22 (1.6) 39 (0.9) 0.002
6 (0.4) 8 (0.6) 11 (0.3) 0.172
0.003
1,274 (91.6) 1,286 (93.9) 4,085 (94.6)
96 (6.9) 71 (5.2) 198 (4.6)
989 (71.1) 943 (69.0) 3,180 (73.9) 0.001
416 (29.9) 493 (36.0) 1,354 (31.4) 0.001
169 (12.2) 154 (11.3) 499 (11.6) 0.736
15 (1.1) 19 (1.4) 57 (1.3) 0.737
1,224 (90.1) 1,219 (90.0) 3,901 (90.9) 0.536
1,023 (73.9) 876 (64.0) 2,949 (68.7) 0.001
1,102 (80.6) 1,099 (81.4) 3,355 (79.2) 0.1609
175 (12.6) 127 (9.3) 329 (7.6) 0.001
11 (0.8) 14 (1.0) 24 (0.6) 0.174
arin; RCA right coronary artery; TIMI Thrombolysis In MyocardialWith S
re
ght hepate ST persisted after multivariable adjustment, compared
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136Figure 2. Treatment Patterns of Early, Late, and Very Late ST
(A) Early stent thrombosis (ST) was more frequently treated with balloon angioplasty alone (POBA), whereas late and very late ST were more frequently treated
with placement of a new drug-eluting stent (DES) (p  0.001). (B) Among subjects with ST of a previously implanted DES, a new DES was more frequently
placed than a bare-metal stent (BMS), regardless of ST timing (p  0.001). (C) Among subjects with ST of a previously implanted BMS, a new BMS was more fre-
quently placed for treatment of early ST, but DES placement was more likely among subjects with very late ST (p  0.001).
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137with early ST, with an adjusted odds ratio (OR) for in-hospital
mortality from late ST of 0.53 (95% confidence interval (CI):
0.35 to 0.79) and 0.58 (95% CI: 0.43 to 0.79) for very late ST
(Table 4). These trends were unchanged and remained statis-
tically significant if the analysis was limited only to patients
presenting with STEMI or non-STEMI.
Discussion
This analysis represents the largest reported series on the
presentation and outcomes of ST in a contemporary PCI
setting. Because of the likelihood of disparate underlying
etiologies of early, late, and very late ST, we hypothesized
that significant differences would exist among these impor-
tant clinical subgroups. The large sample size of the Cath-
PCI registry enabled us to make comparisons among groups
that have not been possible with smaller reported case series.
Three major findings emerged from this study. First, there
were significant differences in the baseline characteristics
and presentation of patients undergoing PCI for treatment
of early, late, and very late ST, supporting the notion of
differing etiologies. Second, most ST cases presented more
Table 3. In-Hospital Outcomes of Patients With ST
Early ST Late ST Very Late ST p Value
Death 110 (7.9) 52 (3.8) 155 (3.6) 0.001
Stroke 14 (1.0) 3 (0.2) 11 (0.3) 0.001
Bleeding event within 72 h 74 (5.4) 43 (3.2) 154 (3.6) 0.003
Values are n (%).
ST stent thrombosis.
Figure 3. In-Hospital Mortality Based on Presentation With Unstable AnginThe p values are: 0.06 for unstable angina; 0.038 for non-STEMI; and 0.001 for STEthan 1 year after stent implantation. Third, ST presenting
within 1 month of stent implantation was associated with a
significantly higher risk of in-hospital mortality than ST
occurring more than 1 month after initial treatment.
Presentation of early, late, and very late ST. We observed
significant baseline differences among patients with ST,
depending on the time since stent implantation. These
differences in baseline clinical characteristics, as a function
of ST timing, lend support to the hypotheses that differing
underlying mechanisms cause early, late, and very late ST.
In the recent RESTART (Registry of Stent Thrombosis of
Sirolimus-Eluting Stents), late ST, compared with very late
ST, was associated with presence of heart failure, hemodi-
alysis, diabetes, and low body mass index (2). Our confir-
mation of a higher prevalence of renal failure among
subjects undergoing PCI for late ST suggests that renal
dysfunction may mediate late ST, possibly due to increased
restenosis with superimposed thrombosis (20,21). Other
studies have also found a lower prevalence of diabetes
among patients with very late ST compared with early ST,
supporting the hypothesis that patients with diabetes may
have an altered acute inflammatory response to stent place-
ment (2,22). A recent study also found an association
between black race and development of ST irrespective of
medication compliance or socioeconomic status (23).
Because we had access only to in-hospital data at the time
of ST, we were unable to investigate further any possible
association between race and development of ST.
The overall rate of presentation with STEMI in our
cohort was similar to previous reports, in which STEMI has
represented 70% to 80% of cases of ST. The higher
n-STEMI, or STEMIa, NoMI. STEMI  ST-segment elevation myocardial infarction.
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138prevalence of complete thrombotic occlusion in the culprit
vessel among patients with early ST may reflect increased
predisposition to thrombosis or increased prevalence of
mechanical complications related to stent implantation. Our
finding that subjects with very late ST were more likely to
have TIMI flow grade 2 or 3 at the time of angiography is
consistent with recent reports (2).
Somewhat surprisingly, we found that only one-half of
patients were treated with aspiration thrombectomy at the
time of ST, and that almost one-half of patients had a new
stent implanted at the time of ST. Although data on
outcomes after ST are limited, the high thrombus burden of
patients with ST would suggest that aspiration thrombec-
tomy might improve short- and possibly long-term out-
comes. Additionally, implantation of a new stent at the time
of ST has been associated with adverse long-term outcomes.
The recent large registry of Japanese patients with ST of
sirolimus-eluting stents had slightly higher rates of aspira-
tion thrombectomy, but patients in that registry were also
Figure 4. In-Hospital Mortality From ST Due to a DES or BMS
There was no difference in mortality for ST due to a BMS versus a DES (p  0
Table 4. Risk-Adjusted In-Hospital Mortality for Early
Category Unadjusted OR
Early ST 7.9% Reference
Late ST 3.8% 0.530
Very late ST 3.6% 0.580
Variables in themodel—age, sex, race, STEMI, cardiogenic shock, prev
highest risk segment category, PCI status, diabetes, and bifurcation le
CHF congestive heart failure; CI confidence interval; CVD caPCI percutaneous coronary intervention; PVD peripheral vascular diseasetreated with new stent implantation 36% of the time.
Further studies of ST with long-term follow-up are needed
to identify management strategies at the time of ST that
improve long-term outcomes.
High prevalence of very late ST. In this study, we found that
ery late ST had a higher prevalence than early or late ST
mong subjects undergoing PCI, with most events occur-
ing more than 2 years after initial stent implantation. Our
ndings do not suggest that very late ST has a higher
ncidence than early or late ST does. The CathPCI registry
s a cross-sectional design, such that the denominator of
atients at risk of ST is uncertain. Previous studies, includ-
ng a Dutch registry of BMS and DES and a Japanese
egistry limited to sirolimus-eluting DES, were prospective
tudies that were able to identify the incidence of ST among
stable population with a defined length of follow-up.
onsistent with this design, those studies suggested that
ery late ST represents only 13% to 30% of all cases of ST
2,14). In comparison, this study identified all-comers with
early ST, 0.8 for late ST, and 0.9 for very late ST). Abbreviations as in Figure 2.
, and Very Late ST
Adjusted OR (95% CI)
ower (95% CI) Upper (95% CI) p Value
0.356 0.790 0.002
0.429 0.785 0.001
F, CVD, PVD, chronic lung disease, GFR, dialysis, NYHA functional class,
cular disease; NYHA New York Heart Association; OR odds ratio;, Late
L
ious CH
sion.
rdiovas; other abbreviations as in Table 1.
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139ST, including those with DES or BMS. These differences
in methodology may account for the high prevalence of very
late ST: early and late ST by definition consist of limited
time frames, whereas very late ST comprises the continued
exposure to a stent from 1 year to many years after initial
implantation. In the CathPCI registry, therefore, the total
number of patient-years with exposure to risk of very late
ST is greater than the patient-year exposure to early or late
ST, so it is not unexpected that very late events would
predominate with this study design. Our findings of a high
population prevalence of very late ST are also similar to that
of a recent multicenter observational study of angiographi-
cally confirmed ST (24).
Nonetheless, our results emphasize the high population
prevalence and public health importance of preventing very
late ST. Recent studies have suggested that very late ST
occurs with a constant incidence of 0.5% per year for BMS
and up to 1.9% per year for DES (22,25). Our findings also
raise concerns that very late ST remains a continued risk
years after PCI; that a significant number of ST occur 2
years after stent implantation; and that further studies are
warranted to address the utility of continuing antiplatelet
therapy beyond 1 year (26).
High mortality of early ST. The in-hospital mortality risk
ssociated with early ST is high and significantly greater
han for patients with late or very late ST. The observed
.15% in-hospital mortality from STEMI from early ST is
ramatically higher than the reported 5.5% mortality from
he overall population of contemporaneous patients in the
CDR registry presenting with STEMI (27). This finding
s consistent with previous studies, suggesting that STEMI
rom ST is associated with higher mortality than STEMI
rom a de novo lesion (3). This increased mortality may
eflect a pre-disposition to thrombosis, higher thrombus
urden, or complications of the initial PCI (28). Notably,
arly ST but not late or very late ST is associated with high
n-treatment platelet reactivity, suggesting that patients
ith early ST may have a pre-disposition to thrombosis and
ubsequent adverse outcomes (29,30). The increased use of
echanical support, glycoprotein IIb/IIIa inhibitors, and
rasugrel among patients with early ST suggest that more-
ntensive therapies were administered to this critically ill
ubgroup. Despite this, the increased risk of mortality in the
arly ST subgroup remained after multivariable adjustment
or baseline factors using a previously validated model for
ortality after myocardial infarction. Given the lack of
herapies specific to ST, and the high risk of mortality,
troke, and bleeding that are associated with it, this study
nderscores the importance of continued efforts to identify
odifiable predictors of this dreaded complication.
Study limitations. The results of this study should be inter-
preted in the context of several potential limitations. First,
because the CathPCI registry does not link patients across
cases, we could not ascertain the details of the initial PCIassociated with the initial stent implantation, such as stent
length, the number of stents implanted, vessel sizes, com-
plications of the initial procedure, or use of intravascular
ultrasound. However, these procedural risk factors for ST
have been well described in previous studies (2,4). Second,
the data collected in the CathPCI registry does not include
compliance to medications. Therefore, we cannot ascertain
the prevalence of medication noncompliance or timing of
antiplatelet discontinuation before ST. Whereas antiplatelet
medication adherence is an important risk factor for ST, the
emphasis of our study was on management and outcomes of
ST, rather than on predictors of developing ST. Third, the
identification of ST was based on operator identification
and report without an angiographic core laboratory. Over-
or underreporting of ST may have occurred; however, we
did employ multiple strategies to ensure that the cases had
a clinical presentation consistent with ST. Fourth, this study
was only able to identify cases of ST for which patients
underwent PCI and, therefore, does not include patients
with probable or possible ST as defined by the Academic
Research Consortium criteria, or ST patients managed
without PCI. This limitation, along with a “survivor bias”
(e.g., ST resulting in pre-hospital death was not captured)
may have resulted in underestimation of the true prevalence
of ST in the entire population of stented patients. Alterna-
tively, there could be a selection bias due to different
proportions of out-of-hospital deaths related to the timing
of ST. Finally, the outcomes of this study are limited to
in-hospital events. As with other observational studies, the
association of early ST with increased mortality does not
necessarily confer causality.
Conclusions
Early, late, and very late ST have significant differences in
presentation that may reflect different underlying causes of
ST as a function of timing after the initial stent implanta-
tion. Most patients with early ST were treated with balloon
angioplasty, whereas patients with very late ST were more
frequently treated with DES. Early ST, compared with late
or very late ST, is associated with higher in-hospital
mortality after multivariable adjustment for baseline clinical
characteristics.
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